US FDA Not Changing Assessment Goals Because of Coronavirus-Mandated Telework
Assessment work also isn’t slowing down, the new and generic drug office directors said in an interview, but approval data offers a note of concern.
You may also be interested in...
New Q&A guidance also states that its near-term focus for resources will be on coronavirus and some other conditions.
New drug approvals dropped, likely because of a new focus on COVID-19 treatments, while generic drug approvals increased.
In less than three weeks, the number of clinical trials for potential treatments has jumped to 72, according to the FDA’s Coronavirus Treatment Acceleration Program.